** U.S.-listed shares of China-based drug developer Zai Lab ZLAB.O fall 6% to $28.11 after the bell

** ZLAB commences public offering of $200 mln of American depositary shares

** Company plans to use the proceeds for general corporate purposes

** ZLAB has 98 mln outstanding shares, with a capitalization of $3 bln market, according to data compiled by LSEG

** Goldman Sachs, Jefferies and Leerink Partners are the joint book-running managers for the offering

** As of last close, ZLAB shares up 9.6% YTD

(Reporting by Arasu Kannagi Basil in Bengaluru)

((ArasuKannagi.Basil@thomsonreuters.com;))